Abstract:HomeStrokeVol. 51, No. 1Letter by Xiang and Cui Regarding Article, “Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Xiang and Cui Regarding Article, “Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation” Qian Xiang, PhD Yimin Cui, MD, PhD Qian XiangQian Xiang Department of Pharmacy, Peking University First Hospital, Xicheng District, Beijing, China Search for more papers by this author Yimin CuiYimin Cui Institute of Clinical Pharmacology, Peking University, Beijing, China Search for more papers by this author Originally published4 Dec 2019https://doi.org/10.1161/STROKEAHA.119.027857Stroke. 2020;51:e9Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: December 4, 2019: Ahead of Print To the Editor:The study by Chen et al1 compared the risks of ischemic stroke (IS) and intracranial hemorrhage of Asian patients with nonvalvular atrial fibrillation and an estimated glomerulus filtration rate >50 mL/min treated with off-label low-dose (10 mg/d) and on-label dosing rivaroxaban. They found that off-label low-dose rivaroxaban was associated with an increased risk of ischemic stroke, with similar risk of intracranial hemorrhage. Per drug label, the on-label dose should be taken with the evening meal. We are very interested to know whether the off-label low-dose was also taken in the same way (ie, with the evening meal)? This information was not provided in the publication.This question is important because timing and type of meal can affect rivaroxaban’s pharmacokinetics and pharmacodynamics based on available literature. Kubitza et al2 compared the pharmacokinetics and pharmacodynamics of rivaroxaban 10 mg single dose between fasting condition and after consumption a high-fat, high-calorie meal in healthy subjects. The geometric mean AUC0-∞ and Cmax were both increased 28% and 41% (P<0.05), respectively, when rivaroxaban was taken with foods. In addition, maximum prothrombin time prolongation and inhibition of FXa activity both increased, from a factor of 1.44 (fasted state) over baseline to 1.53 (fed), and from 33.6% (fasted state) to 42.5% (fed), respectively. A randomized, double-blind, phase 3 study for extended treatment of venous thromboembolism (URL: https://www.clinicaltrials.gov. Unique identifier: NCT02064439) found that the primary efficacy outcome (including symptomatic, recurrent fatal or nonfatal venous thromboembolism and unexplained death for which pulmonary embolism could not be ruled out) occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban (hazard ratio for 20 mg versus 10 mg, 1.08 [95% CI, 0.57–2.06]). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, and 0.4% in the group receiving 10 mg of rivaroxaban. In this study, both dose regimens were given once daily with foods. However, increased risk of thrombosis has been reported in patients taking 15 or 20 mg rivaroxaban on an empty stomach.3In the study of Chen et al,1 the authors did not report the time of rivaroxaban administration and whether it was taken with foods. If a portion of patients in the off-label low-dose group took rivaroxaban 10 mg fasting, the efficacy would be lower compared to that when taken with foods. In such case, the efficacy of off-label low-dose would be biased towards null.Of note, the 10 mg orally once daily is on-label dose for preventing the prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing knee or hip replacement surgery who have lower risk of thrombosis than atrial fibrillation patients. Even in this scenario, in the phase 3 trials (RECORD 1–4 [Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism]) of rivaroxaban for patients undergoing total hip arthroplasty, the 10 mg tablet was administered at every evening (thus, not on an empty stomach). In addition, the dose-ranging study of rivaroxaban for the prevention of venous thromboembolism,4 we found that the protocol directed oral rivaroxaban to be administered within 2 hours after foods. Therefore, the patients in these trails were not fasting.In summary, although the current label states that 10 mg tablet can be taken with or without foods (which may lead to some patients taking it with an empty stomach), available data indicate that efficacy of rivaroxaban could be significantly reduced when taken in fast state, including 10 mg tablet. As such, in comparing efficacy of different rivaroxaban dosages, it is important to report time of administration and whether it is taken fast or with foods.Qian Xiang, PhDDepartment of PharmacyPeking University First HospitalXicheng District, Beijing, ChinaYimin Cui, MD, PhDInstitute of Clinical PharmacologyPeking UniversityBeijing, ChinaAcknowledgmentsThe authors thank Professor Xiaobin Wang for editing the manuscript.Sources of FundingThis study was supported by grants from the National Key R&D Program of China (No. 2016YFC0904900), National Natural Science Foundation (No. 81872940 and No. 81973395) of China.DisclosuresNone.FootnotesStroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 4 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited.References1. Cheng WH, Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation.Stroke. 2019; 50:2574–2577. doi: 10.1161/STROKEAHA.119.025623LinkGoogle Scholar2. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.. J Clin Pharmacol. 2006; 46:549–58. doi: 10.1177/0091270006286904CrossrefMedlineGoogle Scholar3. Beyer-Westendorf J, Siegert G. Of men and meals.J Thromb Haemost. 2015; 13:943–945. doi: 10.1111/jth.12973Google Scholar4. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.Circulation. 2006; 114:2374–2381. doi: 10.1161/CIRCULATIONAHA.106.642074LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails January 2020Vol 51, Issue 1 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.119.027857PMID: 31795901 Originally publishedDecember 4, 2019 PDF download Advertisement SubjectsAnticoagulantsIschemic StrokePharmacology

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation

A systematic review and meta-analysis of the morbidity of efficacy endpoints and bleeding events in elderly and young patients treated with the same dose rivaroxaban

Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria

Standard- Vs. Low-Dose Rivaroxaban in Patients with Atrial Fibrillation: a Systematic Review and Meta-Analysis

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies

A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban

Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study

Variability and Clinical Characteristics of Anti-factor Xa Activity Treated with Rivaroxaban in Chinese Patients Aged ≥ 80 years: A Single-center Study

A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study.

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk

Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation

A real-world study of different doses of rivaroxaban in patients with nonvalvular atrial fibrillation

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies

Efficacy and Safety of Rivaroxaban for Extremely Aged Patients with Venous Thromboembolism: A Retrospective, Cross-Sectional Real-World Study

Potential for anticoagulant therapy in the most vulnerable groups of patients

Application Value and Safety Analysis of Warfarin, Rivaroxaban, and Dabigatran Ester in Elderly Patients With Atrial Fibrillation

Letter by Xiang and Cui Regarding Article, “Low-Dose Rivaroxaban and Risks of Adverse Events in Patients with Atrial Fibrillation”

Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation

Real-world Rivaroxaban Use in Fragile Asian Patients with Atrial Fibrillation: the Impact of Plasma Concentration on Clinical Outcomes

Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study